Success Metrics

Clinical Success Rate
100.0%

Based on 6 completed trials

Completion Rate
100%(6/6)
Active Trials
1(13%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_3
2
25%
Ph not_applicable
2
25%
Ph phase_2
4
50%

Phase Distribution

0

Early Stage

4

Mid Stage

2

Late Stage

Phase Distribution8 total trials
Phase 2Efficacy & side effects
4(50.0%)
Phase 3Large-scale testing
2(25.0%)
N/ANon-phased studies
2(25.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

6 of 6 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

8

all time

Status Distribution
Active(1)
Completed(6)
Other(1)

Detailed Status

Completed6
unknown1
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
8
Active
1
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 24 (50.0%)
Phase 32 (25.0%)
N/A2 (25.0%)

Trials by Status

completed675%
unknown113%
active_not_recruiting113%

Recent Activity

1 active trials
Showing 5 of 8
active_not_recruitingphase_2

Tocotrienol and Bevacizumab in Metastatic Colorectal Cancer

NCT04245865
completedphase_2

Bevacizumab and Tocotrienol in Recurrent Ovarian Cancer

NCT04175470
completedphase_2

Side Effects to FOLFOXIRI + Tocotrienol/Placebo as First Line Treatment of Metastatic Colorectal Cancer

NCT02705300
completedphase_2

Preoperative Use of Tocotrienol From Annatto Bixa Orellana L. in Breast Cancer Patients: a Prospective Clinical Trial.

NCT04496492
unknownphase_3

Stroke and Tocotrienol: Unique Role in Neuroprotection

NCT02263924
View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials
NCT04245865Phase 2

Tocotrienol and Bevacizumab in Metastatic Colorectal Cancer

Active Not Recruiting
NCT04175470Phase 2

Bevacizumab and Tocotrienol in Recurrent Ovarian Cancer

Completed
NCT02705300Phase 2

Side Effects to FOLFOXIRI + Tocotrienol/Placebo as First Line Treatment of Metastatic Colorectal Cancer

Completed
NCT04496492Phase 2

Preoperative Use of Tocotrienol From Annatto Bixa Orellana L. in Breast Cancer Patients: a Prospective Clinical Trial.

Completed
NCT02263924Phase 3

Stroke and Tocotrienol: Unique Role in Neuroprotection

Unknown
NCT00889434Not Applicable

Efficacy and Safety Study of EGCG/Tocotrienol in 18 Patients With Splicing-mutation-mediated Cystic Fibrosis (CF)

Completed
NCT01973400Phase 3

Neuroprotection by Tocotrienols in Type 1 and Type 2 Diabetes Mellitus

Completed
NCT01185769Not Applicable

Study of Tocotrienol Absorption and Distribution Under Different Fat Status

Completed

All 8 trials loaded

Drug Details

Intervention Type
DIETARY SUPPLEMENT
Total Trials
8